Pipeline

A new generation of medicines.

Orphai Therapeutics is advancing the following drugs into clinical trials/development: LAM-001 for Group 1 and Group 3 Pulmonary Hypertension (PH) and Bronchiolitis Obliterans Syndrome post lung transplant (BOS).

Phase 1

Phase 2

Program

LAM-001

Group 1 and Group 3 Pulmonary Hypertension

Hide Details

Preclinical

Phase 1

Phase 2

Phase 3

Program

LAM–001

Bronchiolitis Obliterans post Lung Transplant

Hide Details

Preclinical

Phase 1

Phase 2

Phase 3

Program

AIT-102*

Transcriptionally Dsregulated Tumors

Hide Details

Preclinical

Phase 1

Phase 2

Phase 3

Program

AIT-101**

Amyotrophic Lateral Sclerosis

Hide Details

Preclinical

Phase 1

Phase 2

Phase 3

* AIT-102 is being funded non-dilutively
** Further development of AIT-101 is on hold pending non-dilutive funding

Pipeline

A new generation of medicines.

Group 1 and Group 3 Pulmonary Hypertension

Bronchiolitis Obliterans post Lung Transplant

Transcriptionally Dsregulated Tumors

Amyotrophic Lateral Sclerosis

Publications

Trials

Orphai Therapeutics

Company

Social